<DOC>
	<DOCNO>NCT00989131</DOCNO>
	<brief_summary>RATIONALE : Paclitaxel one widely use human anticancer agent . Paclitaxel low degree solubility Cremophor EL typically use solubiliser . Cremophor EL know cause hypersensitivity reaction life-threatening . As Paclical® contain Cremophor EL , hypersensitivity reaction expect less . PURPOSE : To study efficay safety two different formulation paclitaxel , Paclical® Taxol® .</brief_summary>
	<brief_title>Study Paclitaxel Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histological cytological confirm epithelial ovarian cancer , primary peritoneal cancer fallopian tube cancer . Patients relapse &gt; 6 month end first line second line treatment include platinum base therapy . Prior therapy duration response document CRF descriptive analysis . CA 125 &gt; 2 x upper normal limit ( UNL ) document two occasion , one week interval , accord appendix I , patient group A B , measurable/non measurable disease . Age &gt; 18 year Eastern Cooperative Oncology Group ( ECOG ) performance score 02 Life expectancy &gt; 12 week Patient blood count baseline : Absolute neutrophil count ( ANC ) &gt; 1,5 x 109 / L. Platelet count &gt; 100 x 109 / L Haemoglobin ( Hb ) ≥9g/dl ( post transfusion ) Alanine Aminotransferase ( ALT ) and/or Aspartate Aminotransferase ( AST ) &lt; 2 x UNL Total bilirubin ≤1.5 x UNL . Adequate renal function define serum creatinine &lt; 2.0 mg/dl 177μmol/l . Alkaline phosphatase ( ALP ) &lt; 2.5 x UNL Signed informed consent obtain Patient peripheral neuropathy grade ≥ 2 per NCICTCAE version 3.0 Surgical procedure due progressive disease within 4 week CA125 measurement Patient receive concurrent hormonal , immuno , radiotherapy . Treatment must stop least 4 week start drug treatment ( Day 1 , Cycle 1 ) . Bowel obstruction screen Tumours origin histology Patient childbearing potential , practise adequate contraception , pregnant lactate woman Patient history severe allergy severe hypersensitivity study drug Any uncontrolled medical problem opinion investigator would preclude safe administration study drug , e.g . heart , lung kidney disease , suspicion brain metastasis mental disorder make patient unable participate study Participation investigational drug study within 4 week prior study treatment ( Day 1 , Cycle 1 )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Ovarian Cancer</keyword>
</DOC>